Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
PRLog (Press Release) - Jul. 14, 2013 - MONMOUTH JUNCTION, N.J. -- MONMOUTH JUNCTION, N.J. - Cancer biomarkers allow differentiating malignant from nonmalignant biliary stenoses from bile samples via comparative proteomic analysis of bile. Authors Farina et al published an article in the journal Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics titled, ‘Bile carcinoembryonic cell adhesion molecule 6 (CEAM6) as a biomarker of malignant biliary stenoses’ which cites Cleanascite™ from Biotech Support Group to delipidate bile samples. Bile samples were centrifuged and the supernatant was delipided with Cleanascite™ followed by ultrafiltration. Cleanascite™’s protocol is compatible with samples in which the actual lipid concentration in biological samples varies and different sample volumes are easily scaled. The reagent is a solid-phase, non-ionic adsorbent supplied as a suspension in saline, ready for use. Simply add, centrifuge and/or filter. The clarified supernatant is ready for subsequent downstream processing or analysis. Comparative proteomic biomarker discovery experiments from bile samples of malignant or benign biliary stenosis identified 66 proteins and 7 proteins were elevated in malignant/nonmalignant disease. A cell surface protein, carcinoembryonic cell adhesion molecule 6 (CEAM6), which is associated with cancer was identified via immunoblot. ELISA confirmed CEAM6 as a clinically relevant cancer biomarker of biliary cancers.
For detailed protocols of the published article click http://www.sciencedirect.com/science/article/pii/S1570963...
Characteristics of Cleanascite™ Lipid Removal Reagent and Clarification
Helps purify antibodies, recombinant proteins, nucleic acids, proteoglycans
Ideal for clarifying ascites, serum, cell & tissue culture, bile and organ homogenates
Clarifies saliva and fecal components
Very low protein binding
Does not bind to DNA, RNA, enzymes and proteins
Leaves glycoproteins, antibodies, nucleic acids, hemoglobin, proteoglycans, nucleic acids, serum components(such as hormones, nutrients, globulins, clotting factors, transport proteins) alone
Extends the life of membrane and chromatographic columns.
Enrichment of delipidated tissue samples
Ideal for delipidation treatments for downstream processing of large-scale therapeutic proteins, enzymes and monoclonal antibodies.
Selectively removes lipids, cell debris, lipoproteins, floating fats, impurities from cohn paste, transgenic milk, egg yolk and biological samples for pretreatment of samples prior to purification.
For more information visit: Cleanascite™ Lipid Removal Reagent and Clarification http://www.biotechsupportgroup.com/node/73
About Biotech Support Group LLC
Biotech Support Group LLC is a leading provider of genomics and proteomics sample preparation products and enrichment reagent kits as well as integrated biotechnology services for life sciences research, biomarker and drug discovery. Based in New Jersey, it’s principal products include: AlbuVoid™ for albumin depletion, Cleanascite™ for lipid adsorption and clarification, NuGel™ for passivated silica-based affinity chromatography, and ProCipitate™ & ProPrep™ for nucleic acid isolation. Currently, Biotech Support Group LLC and ProFACT Proteomics Inc., are collaborating on the development of a proteomics platform used in functional profiling for proteomic analysis and a separations method for generating sub-proteomes used in biomarker and functional proteomic prospecting. For more information, go to: www.biotechsupportgroup.com
CONTACT:
Dr.Swapan Roy
Biotech Support Group
1 Deer Park Drive, Suite M,
Monmouth Junction, NJ 08852, USA
732-274-2866
sales@biotechsupportgroup.com
References:
Bile
Farina, Annarita, et al. “Bile carcinoembryonic cell adhesion molecule 6 (CEAM6) as a biomarker of malignant biliary stenoses.” Biochimica et Biophysica Acta (BBA)-Proteins and Proteomics (2013).
Boschetti, Egisto, and Pier Giorgio Righetti. Low-Abundance Proteome Discovery: State of the Art and Protocols. Newnes, 2013.
Wang W, Ai KX, Yuan Z, Huang XY, Zhang HZ.Different Expression of S100A8 in Malignant and Benign Gallbladder Diseases.Digestive diseases and sciences. 2012.
Hauser-Davis RA, Lima AA, Ziolli RL, Campos RC.First-time report of metalloproteinases in fish bile and their potential as bioindicators regarding environmental contamination. Aquatic Toxicology.2012;110-111:99-106
Farina A, Dumonceau JM, Frossard JL. Proteomic Analysis of Human Bile from Malignant Biliary Stenosis Induced by Pancreatic Cancer Journal of Proteome Research.2009; 8(1):159-69
Guerrier L, Claverol S, Finzi L et al. Contribution of solid-phase hexapeptide ligand libraries to the repertoire of human bile proteins. Journal of Chromatography.2007;1176(1-2):192-205
Chen Bo, Zheng Jian-wei, Wang Jian-ming, et al. Establishment and preliminary analysis of a 2-D human biliary map Chinese Journal of Hepatobiliary Surgery.2007
Chen B, Dong JQ, Chen YJ et al Two-dimensional electrophoresis for comparative proteomic analysis of human bile. Hepatobiliary & pancreatic diseases international.2007 Aug;6(4):402-6
Guerrier L, Claverol S, Finzi L et al Contribution of solid-phase hexapeptide ligand libraries to the repertoire of human bile proteins.Journal of Chromatography A.2007;1176(1-2):192-205
Kristiansen TZ, Bunkenborg J, Gronborg M et al A Proteomic Analysis of Human Bile Molecular and Cellular Proteomics.2004;3:715-728
Suggested References
Metzger, Jochen, et al. “Urine proteomic analysis differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders.” Gut 62.1 (2013): 122-130.
Kikkawa, Shintaro, et al. “Identification of a Novel Biomarker for Biliary Tract Cancer Using Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry.” International journal of proteomics 2012 (2012).
Shen, Jian, et al. “Comparative Proteomic Profiling of Human Bile Reveals SSP411 as a Novel Biomarker of Cholangiocarcinoma.” PloS one 7.10 (2012): e47476.
Farina, Annarita, et al. “A step further in the analysis of human bile proteome."Journal of proteome research 10.4 (2011): 2047-2063.
Barbhuiya, Mustafa A., et al. “Comprehensive proteomic analysis of human bile.” Proteomics 11.23 (2011): 4443-4453.
Shigehara, Kengo, et al. “Real-time PCR-based analysis of the human bile microRNAome identifies miR-9 as a potential diagnostic biomarker for biliary tract cancer.” PLoS One 6.8 (2011): e23584.
Chapman, M. H., et al. “Circulating Cyfra 21-1 Is A Highly Specific Diagnostic And Prognostic Biomarker In Biliary Tract Cancer.” (2009): A18-A19.
Farina, Annarita, Jean-Marc Dumonceau, and Pierre Lescuyer. “Proteomic analysis of human bile and potential applications for cancer diagnosis.” Expert Review of Proteomics 6.3 (2009): 285-301.
Bonney, Glenn K., et al. “Circulating markers of biliary malignancy: opportunities in proteomics?.” The lancet oncology 9.2 (2008): 149-158.
Help employers find you! Check out all the jobs and post your resume.
